# US 2012/0252728 A1 · Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252728 A1
- Document ID: US20120252728A1
- Status: Published application
- Kind: A1
- Application number: 13/389,410
- Filed: 2010-08-05
- Published: 2012-10-04
- Earliest claimed: 2009-08-07
- Assignees: MannKind Corporation
- Inventors: Peter Richardson; Enda Kenny; Per Hellstrom; Marshall L. Grant; Grayson W. Stowell; Scott Daniels; Anthony Smithson; Stephanie Greene
- Web page: https://patentgrep.com/patent/US20120252728A1

## CPC

- C07K 14/605: Glucagons
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/1682: {Processes}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/26: Glucagons
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.

## Claims

### Claim 1

A pharmaceutical composition comprising Val (8) glucagon-like peptide-1 (GLP-1) and a diketopiperazine or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the composition is an inhalable dry powder composition.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said diketopiperazine is a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said diketopiperazine comprises a diketopiperazine salt.

### Claim 5 (depends on 3)

The composition of claim 3, wherein said diketopiperazine is 2,5-diketo-3,6-di(4-fumaryl-aminobutyl)piperazine.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said Val (8) GLP-1 is an amidated Val (8) GLP-1.

### Claim 7

A process for forming a particle comprising Val (8) GLP-1 and a diketopiperazine comprising the steps of:
providing a Val (8) GLP-1;
providing a diketopiperazine in a form selected from particle-forming diketopiperazine, diketopiperazine particles, and combinations thereof; and
combining said Val (8) GLP-1 and said diketopiperazine in the form of a co-solution, wherein said particle comprising said Val (8) GLP-1 and said diketopiperazine is formed.

### Claim 8 (depends on 7)

The process of claim 7, further comprising removing a solvent from said co-solution by lyophilization, filtration, or spray drying.

### Claim 9 (depends on 8)

The process of claim 8, wherein said particle comprising said Val (8) GLP-1 and said diketopiperazine is formed by removing said solvent.

### Claim 10 (depends on 8)

The process of claim 8, wherein said particle comprising said Val (8) GLP-1 and said diketopiperazine is formed prior to removing said solvent.

### Claim 11 (depends on 7)

The process of claim 7, wherein said Val (8) GLP-1 is provided in the form of a solution comprising a Val (8) GLP-1 concentration of about 0.001 mg/ml-50 mg/ml.

### Claim 12 (depends on 11)

The process of claim 11, wherein said Val (8) GLP-1 is provided in the form of a solution comprising a Val (8) GLP-1 concentration of about 0.1 mg/ml-10 mg/ml.

### Claim 13 (depends on 11)

The process of claim 11, wherein said Val (8) GLP-1 is provided in the form of a solution comprising a Val (8) GLP-1 concentration of about 0.25 mg/ml.

### Claim 14 (depends on 7)

The process of claim 7, wherein said diketopiperazine is provided in the form of a suspension of diketopiperazine particles.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The process of claim 14, further comprising adding an agent to said suspension, wherein the agent is selected from the group consisting of salts, surfactants, ions, osmolytes, chaotropes and lyotropes, acids, bases, and organic solvents.

### Claim 17 (depends on 16)

The process of claim 16 wherein said agent promotes association between said Val (8) GLP-1 and said diketopiperazine particles.

### Claim 18 (depends on 17)

The process of claim 17, wherein said agent is sodium chloride.

### Claim 19

A method of administering an effective amount of a Val(8) GLP-1 to a subject in need thereof said method comprising providing to said subject an inhalable dry powder formulation comprising Val(8) GLP-1 and a diketopiperazine, in particularly wherein said administration is carried out by pulmonary delivery.

### Claim 20 (depends on 19)

The method of claim 19, wherein said pulmonary delivery is obtained using a dry powder inhalation system.

### Claim 21 (depends on 19)

The method of claim 19, wherein the dry powder inhalation system comprises a cartridge.

### Claim at position 22

-29. (canceled)
